TerminatedPhase 2NCT03327727
VL-2397 Compared to Standard First-Line Treatment for Invasive Aspergillosis (IA) in Adults
Studying Aspergillosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Vical
- Principal Investigator
- Mammen P Mammen, MD, FIDSAVical
- Intervention
- Investigational Agent: VL-2397(drug)
- Enrollment
- 4 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2018 – 2019
Study locations (28)
- University of Alabama at Birmingham Hospital, Division of Infectious Diseases, Birmingham, Alabama, United States
- UC San Diego Moores Cancer Center, La Jolla, California, United States
- UC Davis Health, Dept. of Internal Medicine, Div. of Infectious Diseases, Sacramento, California, United States
- Christiana Care Health Services, Department of Medicine, Newark, Delaware, United States
- Medical College of Georgia at Augusta University, Augusta, Georgia, United States
- DMC Harper University Hospital, Detroit, Michigan, United States
- University of Minnesota, Department of Medicine, Minneapolis, Minnesota, United States
- Washington University School of Medicine, Division of Infectious Disease, St Louis, Missouri, United States
- The University of Texas Health Science Center, Department of Internal Medicine, Houston, Texas, United States
- Fred Hutchinson Cancer Research Center (FHCRC), Seattle, Washington, United States
- Medical College of Wisconsin, Milwaukee, Wisconsin, United States
- University Hospital Antwerp (UZA), Department of Hematology, Edegem, Antwerp, Belgium
- General Hospital Saint-Jan, Department of Hematology, Bruges, Belgium
- Jules Bordet Institute, Department of Infectious Disease, Brussels, Belgium
- University Hospitals Leuven, Campus Gasthuisberg, Department of Hematology, Leuven, Belgium
- +13 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03327727 on ClinicalTrials.govOther trials for Aspergillosis
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGNCT07238114Liver Cirrhosis Patients With Invasive Pulmonary Aspergillosis: in Depth Understanding Clinical Host Risk FactorsUniversitaire Ziekenhuizen KU Leuven
- RECRUITINGPHASE2NCT06794554Rezafungin for Treatment of Chronic Pulmonary Aspergillosis (CPA) in Adults With Limited Treatment OptionsMundipharma Research Limited
- RECRUITINGNCT07313527PCR for Aspergillus Fumigatus in Blood and Bronchoalveolar Lavage Fluid for Monitoring Cases of Invasive Aspergillosis: What is Its Prognostic ValueUniversity Hospital, Strasbourg, France
- ACTIVE NOT RECRUITINGNCT06583512Treatment Duration of IPAPeking University People's Hospital
- RECRUITINGNCT06885905Impact of Chronic Pulmonary Aspergillosis (CPA) on Health Status and Well-beingImperial College London
- RECRUITINGNANCT06440915Study on Theraputic Drug Monitoring and Phamacokinetics of Isavuconazole in ChildrenShanghai Children's Medical Center
- RECRUITINGPHASE3NCT06447402A Trial to Compare Nebulized Amphotericin B and Nebulized Normal Saline as Maintenance in Patients With Chronic Pulmonary AspergillosisPost Graduate Institute of Medical Education and Research, Chandigarh
- RECRUITINGPHASE2NCT05653193Interferon-gamma as Adjunctive Therapy in Chronic Pulmonary Aspergillosis: a Randomised Feasibility StudyManchester University NHS Foundation Trust